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Immune checkpoint inhibitors (ICIs) are designed to reinvigorate antitumor immune
responses by interrupting inhibitory signaling pathways and promote the immunemediated elimination of malignant cells. Although ICI therapy has transformed the
landscape of cancer treatment, only a subset of patients achieve a complete
response. Focused ultrasound (FUS) is a noninvasive, nonionizing, deep penetrating
focal therapy that has great potential to improve the efﬁcacy of ICIs in solid tumors.
Five FUS modalities have been incorporated with ICIs to explore their antitumor effects in
preclinical studies, namely, high-intensity focused ultrasound (HIFU) thermal ablation, HIFU
hyperthermia, HIFU mechanical ablation, ultrasound-targeted microbubble destruction
(UTMD), and sonodynamic therapy (SDT). The enhancement of the antitumor immune
responses by these FUS modalities demonstrates the great promise of FUS as a
transformative cancer treatment modality to improve ICI therapy. Here, this review
summarizes these emerging applications of FUS modalities in combination with ICIs. It
discusses each FUS modality, the experimental protocol for each combination strategy,
the induced immune effects, and therapeutic outcomes.
Keywords: focused ultrasound, immune checkpoint inhibitor, antitumor immune response, combination therapy,
high-intensity focused ultrasound, low-intensity focused ultrasound

INTRODUCTION
Immune checkpoint inhibitor (ICI) therapy has revolutionized the paradigm of cancer
immunotherapy. Under normal physiological conditions, immune checkpoints are crucial to
maintaining immune tolerance. However, in the tumor environment, tumor cells hijack these
inhibitory mechanisms to avoid antitumor immune responses. ICIs are monoclonal antibodies that
disrupt the engagement of immune checkpoints, which enables tumor-reactive T cells to overcome
inhibitory mechanisms and mount effective antitumor immune responses [1]. The United States
Food and Drug Administration (FDA) has approved ICIs that target cytotoxic T lymphocyteassociated protein-4 (CTLA-4), programmed cell death-1 (PD-1), and programmed cell death-ligand
1 (PD-L1) for the treatment of a wide variety of cancers [2]. Despite the clinical success of ICIs,
advancing clinical applications of ICIs face challenges related to both efﬁcacy and safety. Most cancer
patients are unable to derive durable remission, while >50% of cancer patients develop immune
adverse events after they receive ICIs [3]. The combination of multiple ICIs with other cancer
therapies has improved cancer treatment by enhancing direct tumor killing and indirect antitumor
immunity [4].
The past two decades have witnessed exciting breakthroughs in the clinical translations of focused
ultrasound (FUS) modalities for cancer treatment [5]. FUS concentrates extracorporeally generated
ultrasound energy through the body to a tight focus with an exceptional spatial resolution (on the
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millimeter scale) and deep penetration depth. The focal point can
be mechanically and electronically steered in three-dimensional
space to form a sonication volume that conforms to the shape of
the target. FUS therapy is often performed under the guidance of
magnetic resonance imaging or ultrasound imaging [6]. As a
promising therapeutic technology, FUS has the unique combined
advantages
of
being
noninvasive,
nonionizing,
nonpharmaceutical, spatially targeted, and deeply penetrating
the body. Since 2017, ﬁve FUS modalities, including highintensity focused ultrasound (HIFU) thermal ablation [7–11],
HIFU hyperthermia [12], HIFU mechanical ablation [13–17],
ultrasound-targeted microbubble destruction (UTMD) [18–20],
and sonodynamic therapy (SDT) [21, 22], have been investigated
in combination with ICIs for treating solid tumors in mouse
models. The enhancement of antitumor immune responses by
these FUS modalities demonstrated the great promise of FUS as a
transformative cancer treatment modality to improve ICI
therapy.
In this review, we provide a brief introduction of ICI therapy
basics and discuss the challenges facing ICI therapy. We then
introduce each FUS-enhanced ICI therapy and summarize the
therapeutic outcomes achieved by the combination therapy.
Finally, we discuss the limitations of existing studies and
provide future perspectives.

lung cancer (NSCLC), head and neck squamous cancers,
urothelial carcinoma, gastric adenocarcinoma, mismatchrepair-deﬁcient solid tumors, and classic Hodgkin lymphoma.
Many clinical studies with ICIs are currently underway to test
their efﬁcacy in various other diseases.
Despite the clinical success of ICIs, ICI therapy faces
challenges related to both efﬁcacy and safety. With regard to
ICI efﬁcacy, the majority of patients do not beneﬁt from the
treatment, and some responders relapse after a period of
response. Ongoing studies indicate that both tumor cellintrinsic and tumor cell-extrinsic factors contribute to the
resistance mechanisms [27]. Tumor cell-intrinsic factors
include lack of tumor-associated antigens (TAAs), ineffective
antigen presentation, activation of oncogenic pathways, and
insufﬁcient interferon-γ (IFN-γ) signaling. Tumor cellextrinsic factors are within the TME and include exhausted
CD8 T cells, regulatory T cells (Tregs), myeloid-derived
suppressor cells (MDSCs), and other immunosuppressive cells
and factors. With regard to safety, a signiﬁcant number of
patients on ICIs develop immune-related adverse events
affecting almost every organ. Immune-related adverse events
occur when ICIs result in an immune-based attack on normal
tissue. These events, such as dermatitis, thyroiditis, pneumonitis,
colitis, hepatitis, and nephritis, are unpredictable, heterogeneous,
and in some instances life-threatening. Management of these
adverse events remains a challenge [28]. These challenges call for
concepts to maximize the clinical beneﬁts of ICIs in combination
with other therapies. An abundance of clinical trials are currently
underway in evaluating the combination of ICIs with other
immunotherapies, chemotherapy, radiotherapy, or targeted
therapies. Strategies that can improve antigen presentation and
immune recognition, reinforce the activity and inﬁltration of
CD8 T cells, and reduce immunosuppression can potentially be
combined with ICIs to improve the efﬁcacy of ICI therapy [27].
Meanwhile, novel drug delivery strategies that enable the targeted
delivery of ICIs within the TME have the potential to reduce the
toxicities associated with ICIs [29, 30].
FUS is a promising platform technology to be combined with
ICIs to improve its efﬁcacy and safety. Various FUS therapeutic
modalities have been developed, and some of them have been
used in the clinic for the treatment of various diseases (Table 1).
Among them, HIFU thermal ablation has been approved by the
FDA for the treatment of prostate cancer, uterine ﬁbroids, bone
metastasis, and essential tremor and has been used worldwide for
the treatment of various diseases. Although other FUS modalities,
including HIFU hyperthermia, HIFU mechanical ablation,
UTMD, and SDT, have not been approved for clinical use,
clinical studies are currently ongoing, with multiple studies
already reported. Advances in the clinical applications of these
FUS techniques have encouraged new studies to combine FUS
with ICIs, as summarized in Table 2. The effectiveness of FUSenhanced ICI therapy is often demonstrated by increased tumor
inﬁltrated CD8 T cells, decreased tumor volume, and prolonged
survival. The systemic immune response of ICI therapy can also
be demonstrated by the presence of the abscopal effect, which
occurs when the treatment not only shrinks the targeted tumor
but also leads to shrinkage of untreated tumors elsewhere in the

Immune Checkpoint Inhibitor Therapy
Basics and Challenges
ICIs bind to immune checkpoints, including CTLA-4, PD-1, and
PD-L1, and “release the brakes” on T cells, resulting in anticancer
immune responses. CTLA-4 inhibits T-cell activation by
attenuating T-cell receptor signaling through competing with
the costimulatory molecule CD28 for binding to B7 ligands on
antigen-presenting cells (APCs) [23]. PD-1 regulates T-cell
activation through interaction with its ligand PD-L1. The
engagement of PD-1 and PD-L1 results in a negative
costimulatory signal and leads to T-cell apoptosis, anergy, and
exhaustion [24]. Efﬁcient ICI therapy requires reactivation and
clonal expansion of antigen-experienced T cells present in the
tumor microenvironment (TME) [25]. Initially, naive tumorspeciﬁc CD8 T cells are primed by antigen presentation by APCs
(often referred to as immune priming) and activated in the
presence of costimulatory pathways and cytokines. Tumorspeciﬁc CD8 T cells subsequently differentiate into effector
T cells, undergo clonal expansion, trafﬁc to the TME, and
ultimately kill tumor cells. A subset of effector T cells can
differentiate into memory T cells under the guidance of CD4
T cells and dendritic cells (DCs) to develop long-term
immunologic memory against the tumor.
The introduction of ICI therapy in the clinic has been
considered to be a paramount achievement in cancer
treatment in the last decade [26]. Since 2011, the FDA has
approved ICIs targeting PD-1 (pembrolizumab, nivolumab,
and cemiplimab), PD-L1 (atezolizumab, durvalumab, and
avelumab), and CTLA-4 (ipilimumab). They have produced
remarkable results regarding tumor control in many
malignancies, such as melanoma, metastatic non-small-cell
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TABLE 1 | Overview of different FUS modalities.
Modalities

Commonly used FUS parameters

Physical mechanism

Clinical applications

HIFU thermal
ablation

Continuous (duty cycle  100%) HIFU with
spatial peak temporal average intensity (ISPTA)
>1000 W/cm2 and relative high pressure (a few
MPa) to rapidly heat tumor to >60°C within a few
seconds

Coagulative thermal necrosis due to tissue
absorption of ultrasound energy

HIFU
hyperthemia

HIFU with a high duty cycle (up to 70%) and
relative high pressure (a few MPa) to heat up
tissue to 40–45°C for up to 60 min [35]

Thermally controlled drug release and increasing
blood ﬂow and oxygen

HIFU
mechanical
ablation

HIFU with ISPTA >100 W/cm2 and a low duty
cycle (1–2%) and extremely high pressure
(>10 MPa) to induce mechanical tissue damage
while minimizing heating [49]
LIFU with ISPTA <10 W/cm2 and a low duty cycle
(e.g., 10%) and relative low pressure (<1 MPa)
to induce mechanical effects [42]

High-amplitude HIFU pusles are used to induce
bubble cavitation to fractionate tissue by
mechanical effects

The only modality currently approved for use in
the clinic worldwide for the treatment of a variety
of solid malignant tumors (e.g., tumors in the
pancreas, liver, kidney, bone, prostate, and
breast), benign tumors (e.g., uterine ﬁbroids and
ﬁbroadenomata), and non-tumor diseases (e.g.,
essential tremor and Parkinson’s disease) [32]
Mutiple reported clinical studies of HIFU
hyperthermia to enhance the delivery of
thermosensitive liposomal doxorubicine in
patients with liver tumors [35]
No reported clinical results, but clinical trials
ongoing for the treatment of primary and
metastatic liver tumors (ClinicalTrials.gov
Identiﬁer: NCT04572633)
One reported clinical study of drug delivery using
UTMD in pancreatic patients [51]. Multiple
reported clinical studies on opening the bloodbrain barrier for brain drug delivery in patients
with glioblastoma [52, 53], Alzheimer’s disease
[54], and amyotrophic lateral sclerosis [55]
Several reported clinical studies investigated a
combination of light and ultrasound to stimulate a
sensitizer in patients with a variety of cancer [57]

UTMD

SDT

LIFU with ISPTA <10 W/cm2 and a duty cycle of
10–100% to activate sonosensitizers [56]

Targeted and controlled release of therapeutics,
sonoporation for drug/gene delivery, and
mechanical disruption of the blood vessels and
tumor tissue [50]

Sensitizer-dependent sonochemical or
sonophotochemical reactions in an acoustic ﬁeld
that lead to cytotoxicity [48]

HIFU (high-intesity focused ultrasound), LIFU (low-intensity focused ultrasound), UTMD (ultrasound-targeted microbubble destruction, SDT (sonodynamic therapy).

body. In the following, each FUS-enhanced ICI therapy is
introduced.

explored whether HIFU thermal ablation could be effectively
incorporated with ICIs to boost antitumor immune responses in
murine breast cancer models. Breast cancer is often resistant to
most chemotherapies and molecular targeted therapies, including
ICI therapies [7]. Half of the reported FUS-enhanced ICI studies
summarized in Table 2 used murine breast cancer models. In
Silvestrini’s study, systemic anti-PD-1 antibody (αPD-1) and
local adjuvant, CpG, were administered prior to HIFU thermal
ablation for immunotherapy priming. Only with initial
immunotherapy priming, coincident HIFU thermal ablation
and immunotherapy suppressed tumor growth in both treated
and contralateral nontreated tumors and increased the survival
rate [7]. The potential mechanisms for the enhanced antitumor
response from this multistep protocol were proposed as follows
[8]: immunotherapy priming expanded the number of tumorinﬁltrating CD8+ T cells and macrophages. The subsequent HIFU
thermal ablation released tumor antigens, inﬂammatory
chemokines and cytokines, increased interferon stimulating
genes, and altered the local macrophage phenotype. These
effects led to cross-presentation and cross-priming mediated
by macrophages and DCs, resulting in an effective abscopal
response.
The combination of HIFU thermal ablation with ICIs has also
been explored to treat colorectal tumors since some of them are
not suitable for ICIs [34]. Without immunotherapy priming, the
combination of HIFU thermal ablation with ICIs and local
adjuvants was able to produce therapeutic beneﬁts in
colorectal tumor-bearing mice [9]. HIFU thermal ablation was
followed by direct injection of nanoadjuvants into the ablated site
and intravenous injection of anti-CTLA-4 antibody (αCTLA-4).

High-Intensity Focused Ultrasound Thermal
Ablation-Enhanced Immune Checkpoint
Inhibitor Therapy
HIFU thermal ablation induces thermal coagulation by rapidly
(in a few seconds) heating tissue at the focus to >60°C, often with
high-intensity continuous ultrasound waves. Only tissue within
the focal region is selectively ablated, while tissue in the
ultrasound beam path is spared from ablation [31]. Compared
with other local ablative therapies, such as ablative radiotherapy,
radiofrequency ablation, and cryotherapy, HIFU thermal ablation
is the only noninvasive and nonionizing ablation technique,
allowing the procedure to be performed and repeated without
the need for surgical implantation of applicators and concerns
about radiation-induced toxicities. HIFU thermal ablation causes
very few side effects to normal surrounding tissues, and patient
comfort and safety are maximized [32]. HIFU thermal ablation
has been widely applied for the treatment of a variety of solid
tumors, as well as many other benign diseases in the clinic [32].
HIFU thermal ablation has been reported to increase the release
of damage-associated molecular patterns (DAMPs) and TAAs,
promote DC maturation, increase tumor-inﬁltrating
lymphocytes, and change circulating immunosuppressive
cytokine levels [33], suggesting the potential to improve ICI
efﬁcacy for tumors that do not respond well to ICIs.
The ﬁrst study on therapeutic ultrasound-enhanced ICI
therapy was reported in 2017 by Silvestrini et al. [7]. They
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TABLE 2 | Summary of therapeutic ultrasound-enhanced ICI therapies.
References

Cell/mouse
(tumor model)

FUS parameters

Combined FUS and ICI
protocol

Key results
from combination
therapy

HIFU thermal
ablation

Silvestrini et al. [7]

NDL/FVB/n (orthotopic breast cancer)

3 MHz, 3.1 MPa, T > 65°C, target:
circular pattern within 1–2 mm of the
tumor edge

Distant tumor leukocytes ↑ and CD8+ ↑; spleen
IFN-γ+CD8+ ↑; treated and distant tumor volume
↓; survival ↑

Chavez et al. [8]

NDL/FVB/n (orthotopic breast cancer)
PyMT/PyVT (spontaneous breast
cancer)

3 MHz, T > 60°C, target: 2–3 mm
within tumor

Han et al. [9]

CT26/BALB/c (subcutaneous
colorectal cancer)

4 MHz, 43 W, FUS on  1 s, FUS off 
5 s for a single point, repeat 20 rounds
to completely eliminate tumor

Sheybani
et al. [10]

4T1/BALB/c (subcutaneous breast
cancer)

Fite et al. [11]

NDL/FVB/n (orthotopic breast cancer)

3 MHz, 15 W, FUS on  10 s for each
sonication, target: ∼10–20% of total
tumor volume
3 MHz, 3.1 MPa, T > 65°C, circular
pattern within 1–2 mm of the tumor
edge

Kheirolomoom
et al. [12]

NDL/FVB/n (orthotopic breast cancer)
PyMT/PyVT (spontaneous breast
cancer)

Adjuvant CpG (i.t.) injected to single tumor on
days 21, 24, 28, 31, 38, 45; αPD-1 (i.p.)
injected on days 21, 28, and 35; HIFU
thermal ablation applied to tumor on days
31, 38, 45
Adjuvant CpG (i.t.) injected to single tumor on
days 21, 24, 28, 31; αPD-1 (i.p.) injected on
days 21, 28, 35, HIFU thermal ablation
applied to tumor on day 31
For metastatic tumor: HIFU thermal ablation
performed to remove tumor on day 7;
adjuvants directly injected into ablated site
afterward; αCTLA-4 (i.v.) injected on days 8,
10, 12, 14
For recurrent tumor: HIFU thermal ablation
performed to remove tumor on day 7,
adjuvants directly injected into ablated site
afterward; tumor rechallenged on day 47;
αCTLA-4 (i.v.) injected on days 48, 50, 52, 54
Every 3 days for a total of ﬁve doses of αPD-1
(i.p.) injected prior to or with HIFU thermal
ablation with gemcitabine
Adjuvant CpG (i.t.) injected to single tumor on
days 21, 24, 28, 30; αPD-1 (i.p.) injected on
days 21, 28, 34, HIFU thermal ablation
applied to tumor on day 30
Copper-doxorubicin-loaded temperaturesensitive liposomes (i.v.) injected on day 31,
HIFU hyperthermia applied to tumor
afterward; adjuvant CpG (i.t.) injected to
single tumor on days 21, 24, 28, 35, 49;
αPD-1 (i.p.) injected on days 21, 28, 35

4

FUS modality

1.5 MHz, PNP 2.5 MPa, PRF 100 Hz,
pulse length 0–7 ms, heating at 42°C
for 5 min before and 20 min post
liposome injection

Tumor volume ↓

Treated tumor IL-6 and IL-β mRNA ↑; treated
tumor MDSCs ↑; distant tumor MDSCs ↑

Treated and distant tumor CD8+ ↑; treated and
distant tumor volume ↓; survival ↑

(Continued on following page)
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HIFU
hyperthermia

Treated tumor interferon-stimulated gene
expression ↑; treated tumor CD169+DCs ↑ and
CD169+MPs ↑; distant tumor DCs ↑; spleen
CD169+MPs ↑
Distant tumor CD8+/Tregs ↑ and MDSCs ↓;
spleen effector memory T cell
(CD3+CD44HiCD62Lo) ↑; serum IFN-γ ↑ and TNFα ↑; distant tumor volume ↓; survival ↑; tumor
rechallenge suppressed

FUS modality

References

Cell/mouse
(tumor model)

FUS parameters

Combined FUS and ICI
protocol

Key results
from combination
therapy

HIFU
mechanical
ablation

Wang et al. [13]

GL261/C57BL/6 (subcutaneous
glioblastoma)

1.1 MHz, duty cycle 2%, treatment
duration 2 min

Tumor CD45+ ↑, CD3+ ↑, CD8+ ↑, and IFN-γ ↑;
tumor size ↓; survival ↑; tumor rechallenge
rejected

Eranki et al. [14]

Neuro2a/C57BL/6 (subcutaneous
neuroblastoma)

1.5 MHz, PNP 14 MPa, PRF 1 Hz,
pulse duration 13.33 ms, 5 s/location,
3 locations, cover 2% tumor volume

Perﬂuorocarbon-ﬁlled microshells directly
injected to large tumors (400–700 mm3),
HIFU mechanical ablation applied to tumor
afterward; αPD-1 (i.p.) injected on days 0, 2,
4, 6, 8, 10a
Histotripsy applied to tumor on day 8;
αCTLA-4 (i.p.) + αPD-L1 (i.p.) injected on
days 9, 12, 15

Nam et al. [15]

4TI/BALB/c (subcutaneous breast
caner); CT26/BALB/c (subcutaneous
colorectal cancer)
B16GP33/C57BL/6 (subcutaneous
melanoma)
Hepa1-6/C57BL/6 (subcutaneous
hepatoma)

1.5 MHz, electrical power 525 W, PRF
1 Hz, duty cycle 1%, pulse length
10 ms, 50 pulses
1 MHz, PNP 30 MPa, PRF 100 Hz, 50
pulses, pulse duration 1–2 µs; total
treatment duration 4–15 min
depending on tumor volume

Singh et al. [17]

B16F10/C57/BL-6 (subcutaneous
melanoma)

1.5 MHz, acoustic power 450 W, PRF
1 Hz, duty cycle 1%, cover 40–50% of
the tumor

Li et al. [18]

LLC/C57BL/6 (subcutaneous and
orthotopic lung cancer)

1 MHz, 2.0 W/cm2, duty cycle 50%,
treatment duration 5 min

Bulner et al. [19]

CT26/BALB/c (subcutaneous
colorectal cancer)

1 MHz, PNP 1.65 MPa, pulse length
0.1 ms, duty cycle 10%, wait 20 s after
every 50 pulses, total treatment
duration 2 min

Ilovitsh et al. [20]

NDL/FVB/n (orthotopic breast cancer)

250 kHz, PNP 500 kPa, PRF 30 Hz,
burst length 4 ms, total treatment
duration 3 min

Qu et al. [16]

5
UTMD

Histotripsy applied to tumor on days 6, 7, 8;
αPD-1 (i.p.) injected on day 9, 11, 13

Tumor CD4+ ↑, CD8α+ ↑ and CD8α+CD11c+ ↑;
spleen and TDLN CD8α+CD11c+ ↑; spleen
CD11blow ↑; spleen effector memory T cells (CD4+
or CD8+CD44+hiCD62L+low) ↑; serum IFN-γ↑, IL6↑ and IL-10↓; complete abscopal response;
survival ↑; transferred T cells suppressed tumor in
recipients
Tumor CD8+ ↑, CD8+CD107α+ ↑, CD8+PD-1+ ↑
and MDSCs ↓; tumor volume ↓; tumor weight ↓
Tumor CD8+ ↑; tumor volume ↓

Tumor growth ↓; survival ↑

Tumor TUNEL ↑, Ki67+ ↓, CD4+ ↑, CD8+ ↑; tumor
growth ↓; body weight loss ↓; survival ↑

Tumor necrosis↑ and growth↓; survival ↑; one
survived mouse suppressed tumor rechallenge

Tumor CD8+ ↑ and F4/80 MPs ↑; treated and
distant tumor growth ↓; survival ↑

(Continued on following page)

Ultrasound-Enhanced Checkpoint Inhibitor Therapy

March 2021 | Volume 9 | Article 636985

For B16GP33 tumor, histotripsy applied to
tumor on day 7; αCTLA-4 (i.p.) injected at
days 6, 9, 12
For Hepa1-6 tumor, histotripsy applied to
tumor on day 10; αCTLA-4 (i.p.) injected on
days 3, 6, 9, 12
Histotripsy applied to tumor (330–400 mm3);
single dose of αCD40 (i.t.) injected afterward
(within 2 h); 3 dose of αCTLA-4 (i.p.) + αPDL1 (i.p.) injected at 3 days interval
Docetaxel and αPD-L1-coloaded
microbubbles (i.v.) followed by LIFU applied
to tumor on days 8, 11, 14, 17, 20 for
subcutaneous tumor and on days 6, 9, 12,
15, 18 for orthotopic tumor
LIFU+microbubbles two repeats with 10 min
interval on day 10–12; αPD-1 (i.p.) injected
on days 0, 3, 6 after LIFU+microbubbles for
acute study and 0, 3, 5, 9, 12 for longitudinal
study
αCD326-loaded microbubbles and pIFN-β
(i.t.) injected followed by LIFU applied to
tumor on day 14; αPD-L1 (i.p.) injected on
days 11, 16

Yuan et al.
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TABLE 2 | (Continued) Summary of therapeutic ultrasound-enhanced ICI therapies.

CT26/BALB/c (colorectal cancer,
subcutaneous and intravenous
injeciton)
Um et al. [22]

Frontiers in Physics | www.frontiersin.org

The nanoadjuvants were formed by loading poly (lactic-coglycolic) acid nanoparticles with either a TLR7 agonist
(imiquimod, R837) or TLR4 agonist (monophosphoryl lipid A,
MPLA). This combination strategy increased the intratumoral
CD8 T cell/Treg ratio, reduced MDSCs within tumors, achieved
complete distant tumor eradication, prolonged mouse survival,
and prevented tumor recurrence, indicating the generation of
sustained immune memory against colorectal tumors. In
contrast, none of the mice given HIFU thermal ablation plus
either nanoadjuvants or αCLTA-4 survived [9], which suggests
that additional agents (e.g., adjuvants, chemotherapeutics) may
be required for the success of HIFU thermal ablation and ICI
combination treatment. Another study reported that initiating
αPD-1 treatment prior to versus shortly after HIFU thermal
ablation with chemotherapy did not bear a marked difference
in primary tumor growth in a murine breast cancer model [10].
These studies suggest that the optimal protocol for HIFU
thermal ablation-enhanced ICI therapy may depend on the
tumor model, the type of adjuvants used, with or without
immunotherapy priming, and the HIFU ablation protocol.
HIFU thermal ablation as a combination therapy with ICIs
has the potential limitation that excessive heat generation by
HIFU thermal ablation may induce protein denaturation and
inactivate antigen presentation [13]. Meanwhile, HIFU thermal
ablation was also reported to increase tumor inﬁltrated MDSCs
and Tregs at both directly treated and distant tumors, leading to
inhibition of antitumor immunotherapy [11]. These negative
effects highlight the complexity of combining HIFU thermal
ablation with ICI therapy.

a
Days referred to treatment start date, all the other days referred to tumor implantation date.
T (temperature), PNP (peak negative pressure), PRF (pulse repetition frequency), i. p. (intraperitoneally), i. v. (intravenously), i. t. (intratumorally), FUS (focused ultrasound), HIFU (high-intensity focused ultrasound), LIFU (low-intensity focused
ultrasound), UTMD (ultrasound-targeted microbubble destruction), SDT (sonodynamic therapy), Tregs (regulatory T cells), MPs (macrophages), MDSCs (myeloid-derived suppressor cells), TDLN (tumor-draining lymph nodes), IFN-c
(interferon-gamma), TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin 6), IL-1β (interleukin 1 beta), IL-10 (interleukin 10), TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling), CpG (cytosine-phosphodiester-guanine
oligodeoxynucleotide).

Tumor CD8+ ↑; tumor volume ↓; tumor weight ↓

Sonosensitizers and adjuvant loaded
liposomes (i.v.) injected on days 7, 8, 10, 11;
LIFU applied to tumor 12 and 24 h post
injection; αPD-L1 (i.v.) injected on days 8, 11,
13, 15
Sonosensitizers and gas loaded PEGylated
carboxymethyl dextran (i.v.) injected and
6 hrs later LIFU applied on tumor on days 8,
11, 14; αPD-L1 (i.p.) injected on days 9,
12, 15
1 MHz, 1.5 W/cm2, 50% duty cycle,
treatment duration 5 min
4T1/BALB/c (breast cancer, orthotopic
and intravenous injection); CT26/
BALB/c (subcutaneous colorectal
cancer)
Yue et al. [21]
SDT

Cell/mouse
(tumor model)
References

Acoustic power 10 W, duty cycle 20%,
PRF 1 Hz, treatment duration 10 min

Combined FUS and ICI
protocol
FUS parameters

Tumor leucocytes ↑, CD8+ ↑ and CD8+/Tregs ↑;
serum IFN-γ ↑ and TNF-α ↑; tumor volume ↓;
survival ↑

Ultrasound-Enhanced Checkpoint Inhibitor Therapy

FUS modality

TABLE 2 | (Continued) Summary of therapeutic ultrasound-enhanced ICI therapies.

Key results
from combination
therapy

Yuan et al.

High-Intensity Focused Ultrasound
Hyperthermia-Enhanced Immune
Checkpoint Inhibitor Therapy
HIFU hyperthermia raises tissue temperature within the focal
region to 40–45°C for up to 60 min. It is different from thermal
ablation in that hyperthermia is not intended to produce
substantial cell death directly. Instead, HIFU hyperthermia is
often combined with chemotherapy and radiation therapy or
used for local drug release in combination with temperaturesensitive nanoparticles [35]. HIFU hyperthermia can directly
promote antigen cross-presentation and tumor-reactive T cell
formation and expansion [36].
Kheirolomoom et al. investigated the combination of HIFU
hyperthermia with chemotherapy, CpG, and αPD-1 [12]. HIFU
hyperthermia was utilized to control the release of temperaturesensitive liposomes loaded with a chemotherapy drug,
doxorubicin (Dox). The liposome carrier was designed to
minimize the severe cardiac toxicity of Dox and enhance its
delivery efﬁciency to tumors. Dox released at HIFU
hyperthermia-treated tumors enhanced the presentation of
tumor-speciﬁc antigens at distant tumor sites. Similar to HIFU
thermal ablation [7], only with immunotherapy priming by CpG
and αPD-1, the combined HIFU hyperthermia, Dox-loaded
liposomes, and αPD-1 treatment increased tumor inﬁltrated
CD8 T cells and achieved complete tumor destruction in both
treated and distant tumors as well as prolonged tumor-free
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tumor-free survival and protected against tumor rechallenge,
suggesting the formation of long-term immune memory
against glioblastoma. In a murine neuroblastoma model,
Eranki et al. demonstrated that histotripsy potentially
transformed immunologically "cold" tumors into responsive
"hot’ tumors and provided an efﬁcacious adjuvant to ICI
therapy [14]. Histotripsy followed by systemic injection of
αCTLA-4 and αPD-1 induced signiﬁcant increases in
intratumoral CD4, CD8α, and CD8α+ DCs in regional lymph
nodes and circulating IFN-γ and decreases in circulating IL-10.
Notably, the combination therapy improved long-term survival,
achieved complete bilateral tumor regression, and induced an
effective long-term immune memory response to suppress
subsequent tumor engraftment. Other recent studies found
that histotripsy stimulated more potent intratumoral CD8
T cells and antigen presentation than HIFU thermal ablation
in a murine breast cancer model [15] and melanoma model [16].
One recent study showed that combining histotripsy with
intratumor anti-CD40 agonist antibody, αCTLA-4, and antiPD-L1 antibody (αPD-L1) signiﬁcantly improved the
therapeutic efﬁcacy against ICI refractory murine
melanoma [17].
These ﬁndings [13–16] suggest that HIFU mechanical ablation
alone, without the need for adjuvants, is sufﬁcient to enhance ICI
therapy for the treatment of cancers that are unresponsive to ICIs.
One advantage of HIFU mechanical ablation over HIFU thermal
ablation is that tumor fragmentation instead of tumor
coagulation may protect TAAs and DAMPs from protein
denaturation by excessive heat and stimulate more effective
antitumor immune responses [15, 16, 33, 41].

survival. However, repeated Dox delivery by HIFU hyperthermia
either with or without immunotherapy priming reduced the
complete response rate, which was considered to be caused by
rapid tumor cell death resulting from repeated Dox release that
weakened the impact of local antigen and cytokine release. These
ﬁndings highlighted the importance of the dosing of HIFU
hyperthermia-mediated chemotherapy and the timing of
immunotherapy to augment ICI efﬁcacy for cancer treatment.
These reported studies [7, 9, 10, 12] suggest that neither HIFU
thermal ablation nor HIFU hyperthermia alone is sufﬁcient to
enhance ICI efﬁcacy in murine tumor models. Both FUS
modalities were found to enhance the release of TAAs and
recruitment of CD8 T cells, but in the absence of additional
stimuli (e.g., adjuvants, chemotherapeutics), the recruited CD8
T cells might not have sufﬁcient antigen cross-presentation and
cross-priming mediated by DCs and macrophages [8, 11]. Future
studies are needed to investigate the optimal combination therapy
by HIFU thermal ablation or hyperthermia with ICIs and
adjuvants/chemotherapeutics to achieve systemic, long-term
effects for cancer treatment.

High-Intensity Focused Ultrasound
Mechanical Ablation-Enhanced Immune
Checkpoint Inhibitor Therapy
HIFU mechanical ablation utilizes short pulse lengths
(microsecond to millisecond) and low duty cycles to produce
mechanical ablation of tissues while limiting tissue temperature
increase. The primary physical mechanism of HIFU mechanical
ablation is cavitation, which is deﬁned as the formation,
oscillation, and collapse of bubbles in the acoustic ﬁeld.
Cavitation can induce tissue damage by various mechanisms,
including microjecting, streaming, and shear stresses [37]. The
formation of cavitation in tissue by HIFU can be facilitated by the
injection of exogenously made cavitation nuclei, for example,
microbubbles
or
phase-changing
materials
(e.g.,
perﬂuorocarbon). Without the injection of cavitation nuclei,
cavitation can be initiated using ultrasound pulses with high
tensile pressure, which stretches the tissue and generates
cavitation bubbles in situ. When extremely high tensile
pressures are generated, HIFU can lead to complete
liquefaction of the tumor tissue into submicron fragments,
which is named histotripsy [38]. Several reports have shown
that HIFU mechanical ablation can cause immunogenic cell death
and release tumor debris in situ, promote antigen presentation,
and enhance the inﬂammatory response [33].
The clinical applications of ICIs in brain tumors (e.g.,
glioblastoma and neuroblastoma) have been challenging,
potentially because these tumors harbor a “cold” immune
microenvironment that lacks requisite T cells and sufﬁcient
TAAs and contains high densities of immunosuppressive cell
populations [39, 40]. One recent study demonstrated that HIFU
mechanical ablation combined with silica microshells
mechanically disrupted glioblastoma tumors and augmented
the efﬁcacy of αPD-1 [13]. The combination of HIFU
mechanical ablation with microshells and αPD-1 increased
tumor-inﬁltrating CD8 and IFN-γ+CD8 T cells, prolonged
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Ultrasound-Targeted Microbubble
Destruction-Enhanced Immune Checkpoint
Inhibitor Therapy
There is no consensus regarding the deﬁnition of low-intensity
focused ultrasound (LIFU). It can be regarded as FUS with pulse
intensity similar to that of diagnostic ultrasound. Microbubbles
are made of a phospholipid, surfactant, albumin, or synthetic
polymer shell ﬁlled with a high molecular weight gas with low
water solubility. These microbubbles were initially introduced
into the clinic as ultrasound contrast agents to enhance
ultrasound signals from the blood circulation [42]. Over the
past decades, they have been developed into theranostic
agents. Their shells can be used for disease-speciﬁc targeting
and loaded with drugs as carriers for controlled drug release at the
LIFU-targeted region. Moreover, microbubble cavitation upon
LIFU sonication can generate mechanical forces on surrounding
tissue and induce vascular disruption [43].
PD1/PD-L1 ICIs have been used in the clinic for the treatment
of NSCLC in combination with chemotherapeutic drugs.
However, the combination of these drugs leads to aggravated
cardiotoxicity, hematotoxicity, hepatotoxicity, and neurotoxicity
[44]. Li et al. used microbubbles as carriers of immunotherapy
and chemotherapy drugs to produce antitumor effects while
reducing the toxicities of the drug combination [18]. Docetaxel
was loaded inside the lipid shell of the microbubbles, and αPD-L1
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was conjugated to the surface of the microbubbles. UTMD
improved drug delivery to the tumor potentially through three
combined effects: αPD-L1 on the surface of the microbubbles
speciﬁcally targeted the tumor cells; ultrasound sonication
ruptured the microbubbles and released the carried drug at the
LIFU-targeted tumor site; microbubble cavitation increased
tumor permeability and promoted drug penetration across the
vessel and into the tumor tissue. As a result, this therapeutic
strategy inhibited tumor growth and improved the survival of
mice implanted with tumor cells in the lung. It is worth to point
out that lung diseases are often considered difﬁcult to treat with
FUS because the lungs are air-ﬁlled cavities. However, clinical
studies have combined ultrasound and microbubbles to enhance
drug delivery to the lungs of patients with pneumonia, acute
respiratory distress syndrome, and NSCLC [45, 46]. It was
proposed that because the diseased areas of the lung are ﬁlled
with ﬂuid, ultrasound waves could penetrate through the diseased
area and leave normal air-ﬁlled areas of lung unaffected.
Microbubbles were also used as “anti-vascular” agents to
disrupt blood vessels and increase the antitumor effects of ICI
therapy of colorectal cancer in a study by Bulner et al. [19]. They
found that UTMD alone induced an instant shutdown of blood
ﬂow within tumor tissue and resulted in tumor necrosis in a
mouse model of colorectal cancer. The combination of UTMD
and αPD-1 treatment conferred better tumor growth constriction
and a higher survival rate than USMB or αPD-1 alone and
rejected subsequent tumor rechallenge. However, the results
did not support that the combined UTMD and αPD-1
treatment shifted T-cell subpopulations to a more favorable
antitumor state.
In a murine breast cancer model, UTMD produced triple
antitumor effects simultaneously: carrying an anti-CD326
antibody to target tumor cells, nonviral gene transduction of
IFN-β by sonoporation, and tumor debulking by mechanical
forces [20]. Such proximity of microbubbles to tumor cells using
targeted microbubbles was crucial for effective sonoporation to
transfect tumor cells. IFN-β expression plus αPD-1 led to a
decreased tumor cell population and increased tumorinﬁltrating CD8 T cells. The complete combination treatment
attained greater tumor growth reduction in treated and distant
tumors and prolonged survival than any partial treatments in the
murine breast cancer model.

sufﬁcient immune memory responses to reject subsequent
tumor rechallenge in murine breast and colorectal cancer
models. The SDT-elicited antitumor effects, immune adjuvantcontaining sonosensitizers, and αPD-L1-mediated systemic
antitumor immune response were attributed to the robust
antitumor response.
Recently, Um et al. used nanobubbles loaded with a
sonosensitizer (chlorin e6) for the treatment of pulmonary
metastasis of colorectal cancer [22]. Upon sonication, these
nanobubbles caused cell membrane disruption by cavitation,
which triggers immunogenic cancer cell death and releases
intact DAMPs for in situ cancer vaccination. The combination
of αPD-L1 with nanobubbles loaded with the sonosensitizer
effectively suppressed primary and metastatic tumors, which
suggested that physically induced tumor cell death by the
nanobubbles combined with SDT can augment the efﬁcacy of
ICIs. More work is needed to determine whether this strategy can
improve long-term survival and generate long-lasting immune
memory responses against tumor recurrence.

DISCUSSION
Recent publications have presented exciting and promising
results that FUS modalities can improve ICI therapy.
Combination therapies were reported to suppress tumor
growth, achieve tumor remission, improve long-term survival,
and prevent tumor recurrence for cancer types that are not readily
responsive to ICI treatments. The ﬁeld of FUS-enhanced IC
therapy is still in its infancy, with all existing studies focused
on prooﬁng the concept. Further development of the
combination strategy requires a multidisciplinary approach
with a proper choice of FUS parameters for particular tumors,
a complete examination of the correlation between FUS
parameters and antitumor immune effects, a thorough
evaluation of the biological mechanisms for therapeutic
outcome, and a good understanding of the clinical challenges
in cancer immunotherapy.
Although each FUS modality has the capability to improve ICI
immunotherapy, it is still unknown which regimen has the
greatest potential to combine with ICIs. One major challenge
is the inconsistent reporting of FUS parameters and antitumor
immune effects, which prevents correlating FUS parameters with
antitumor immune effects. It is important to standardize
reporting on FUS procedures to include all key parameters,
such as ultrasound frequency, intensity, pressure, duty cycle,
pulse repetition frequency, sonication target locations, and
sonication duration. It is also critical to establish standards in
reporting antitumor immune effects to enable comparisons
across different studies. Another challenge is that the choice of
the optimal FUS modality to improve ICI immunotherapy may
depend on tumor type.
The biological mechanisms of each FUS-enhanced ICI therapy
remain to be revealed. The reported HIFU thermal ablationenhanced therapy required adjuvants to provide sufﬁcient
antigen cross-presentation and cross-priming for CD8 T cells.
In contrast, HIFU mechanical ablation alone was sufﬁcient to

Sonodynamic Therapy-Enhanced Immune
Checkpoint Inhibitor Therapy
SDT utilizes LIFU to activate sonosensitizers and induces
cytotoxicity [47, 48]. Unlike chemotherapy drugs that have
massive toxicity on healthy cells, SDT induces tumor cell
disruption only at the LIFU-targeted site. Preclinical studies
have found that tumor cell debris generated by SDT could
provide TAAs for initiating antitumor immunological effects
[47, 48]. One report employed SDT using liposomes loaded
with sonosensitizers and adjuvants [21]. Strikingly, SDT
combined with αPD-L1 eradicated the primary tumor,
suppressed distant tumor growth, inhibited whole-body
metastasis in murine breast cancer models and produced

Frontiers in Physics | www.frontiersin.org

8

March 2021 | Volume 9 | Article 636985

Yuan et al.

Ultrasound-Enhanced Checkpoint Inhibitor Therapy

effectively stimulate antitumor immune responses to enhance ICI
therapy. There was only one report on HIFU hyperthermiaenhanced ICI therapy. UTMD has great potential to improve ICI
therapy through targeted and controlled release of therapeutics,
sonoporation, and mechanical disruption of the blood vessels and
tumor tissue. SDT induces tumor cell disruption only at the FUStargeted site, resulting in reduced toxicity. Further investigations
are warrant to better understand the biological mechanisms of
each combination therapy.
FUS-enhanced ICI therapies have already undergone early
stage clinical evaluations. Currently, two clinical trials have begun
to evaluate the combination of HIFU thermal ablation with
pembrolizumab (αPD-1) for the treatment of various advanced
solid tumors, such as melanoma, breast cancer, and Merkel cell
carcinoma (ClinicalTrials.gov Identiﬁer: NCT04116320 and
NCT03237572). The primary outcome will assess a change in
the CD8/CD4 T cell ratio in the ablation zone, and the secondary
outcome will assess adverse events. Meanwhile, one clinical trial
has started evaluating the use of UTMD to enhance the
permeability of the blood-brain barrier without causing
vascular damage to facilitate the delivery of nivolumab (αPD1) to melanoma metastases in the brain and boost immunity in
the brain (NCT04021420).
For the successful clinical translation of FUS-enhanced ICI
therapy, we need strong collaboration between ultrasound

engineers and immunologists. Ultrasound engineers can
optimize FUS parameters to induce the optimal biological
effects that effectively induce antitumor immune responses
with minimized side effects. Immunologists can better
characterize the resulting antitumor immune responses and
therapeutic outcomes. Through appropriate tuning of FUS
exposure conditions and comprehensive immunological
characterization, the prospect of unmasking the utility of FUS
with ICI therapy could be attainable.
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